Alignment Healthcare, Inc.

With $726.3M in cash and $330.0M in debt, ALHC maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company generates $234.6M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 12.5% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 2.1% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $1.43B (2022) to $3.95B (2025), reflecting a 175% increase over the period.

With cash comfortably exceeding debt, ALHC has financial flexibility that may help navigate uncertain periods. The elevated P/E ratio means the stock is priced for significant future growth. If earnings disappoint, the price correction could be sharp. No single metric tells the full story. Reviewing ALHC's risk profile alongside its fundamentals and technical indicators provides a more complete picture.